October 20, 2025

Galliford Try secures place on The Hyde Group’s £3b affordable homes framework

Galliford Try’s Building division has been appointed to all seven lots of The Hyde Group’s new £3 billion Main Contractor framework, covering the East, South and London regions...

Kainos to host Capital Markets Event in London on 22 October 2025

Kainos, the UK-based IT services and software company, will hold a Capital Markets Event for analysts and institutional investors on 22 October 2025 at Investec’s London offices...

Plus500 reports strong Q3 2025 performance as US futures funds surpass $1 billion

Plus500 delivered steady results for Q3 2025, with revenue of $182.7 million and EBITDA of $82.7 million, maintaining a 45% margin. Customer income rose 8% year-on-year to $536.7 million for the first nine months, supported by growth in higher-value clients and strong US futures performance...

Sirius Real Estate acquires €43.7m business park near Munich, expanding German portfolio

Sirius Real Estate has completed the €43.7 million acquisition of a 27,180 sqm business park in Feldkirchen, near Munich. The site, 94% occupied and generating €3.4 million in annual rent, delivers a 7.8% EPRA Net Initial Yield...

B&M lowers FY26 outlook following £7m freight cost adjustment and CFO resignation

B&M European Value Retail has revised its FY26 outlook after identifying around £7 million of overseas freight costs that were not correctly recorded due to a system update earlier in the year...

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...

GlobalData expects FY25 revenue in line with market forecasts

GlobalData reports 13.5% revenue growth in Q3 2025, supported by stronger subscription performance and recent acquisitions. The company expects full-year revenue to meet market expectations, with underlying growth in the low single digits..

EDX Medical secures up to £4m to accelerate diagnostic product development

EDX Medical has raised up to £4 million to advance its digital diagnostic products for cancer, cardiovascular, and infectious diseases. The funding includes a £2 million share placing at 14p per share and a £2 million convertible loan note from founder Professor Sir Chris Evans...
Search

Funds

October 20, 2025

Galliford Try secures place on The Hyde Group’s £3b affordable homes framework

Galliford Try’s Building division has been appointed to all seven lots of The Hyde Group’s new £3 billion Main Contractor framework, covering the East, South and London regions...

Kainos to host Capital Markets Event in London on 22 October 2025

Kainos, the UK-based IT services and software company, will hold a Capital Markets Event for analysts and institutional investors on 22 October 2025 at Investec’s London offices...

Plus500 reports strong Q3 2025 performance as US futures funds surpass $1 billion

Plus500 delivered steady results for Q3 2025, with revenue of $182.7 million and EBITDA of $82.7 million, maintaining a 45% margin. Customer income rose 8% year-on-year to $536.7 million for the first nine months, supported by growth in higher-value clients and strong US futures performance...

Sirius Real Estate acquires €43.7m business park near Munich, expanding German portfolio

Sirius Real Estate has completed the €43.7 million acquisition of a 27,180 sqm business park in Feldkirchen, near Munich. The site, 94% occupied and generating €3.4 million in annual rent, delivers a 7.8% EPRA Net Initial Yield...

B&M lowers FY26 outlook following £7m freight cost adjustment and CFO resignation

B&M European Value Retail has revised its FY26 outlook after identifying around £7 million of overseas freight costs that were not correctly recorded due to a system update earlier in the year...

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...

GlobalData expects FY25 revenue in line with market forecasts

GlobalData reports 13.5% revenue growth in Q3 2025, supported by stronger subscription performance and recent acquisitions. The company expects full-year revenue to meet market expectations, with underlying growth in the low single digits..

EDX Medical secures up to £4m to accelerate diagnostic product development

EDX Medical has raised up to £4 million to advance its digital diagnostic products for cancer, cardiovascular, and infectious diseases. The funding includes a £2 million share placing at 14p per share and a £2 million convertible loan note from founder Professor Sir Chris Evans...
Search

Funds

October 20, 2025

FTSE 100

Funds